Clinical Trial

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein that stimulates the immune system), and cetuximab (a targeted antibody) in treating advanced head and neck cancer. The names of the therapies involved in this study are: * PD-L1 t-haNK cell therapy (a NK cell therapy infusion) * NAI (a type of recombinant human superagonist) * Cetuximab (a type of antibody)
Protocol Amendment History 1 change
notable Sponsor changed: Glenn J. Hanna -> Dana-Farber Cancer Institute 2026-07-31
Trial Details
NCT Number NCT06239220
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: ImmunityBio, Inc.
Conditions Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Enrollment 25 participants
Start Date 2024-02-16
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30